Antiepileptic Drug Selection in Multiple Myeloma
In patients with multiple myeloma requiring antiepileptic therapy, avoid enzyme-inducing antiepileptics (phenytoin, carbamazepine, phenobarbital) and instead use non-enzyme-inducing agents such as levetiracetam, gabapentin, lamotrigine, pregabalin, topiramate, or zonisamide at standard doses.
Rationale for Drug Selection
The primary concern with antiepileptic drugs (AEDs) in multiple myeloma is drug-drug interactions that can compromise both seizure control and cancer treatment efficacy. Enzyme-inducing AEDs significantly reduce the effectiveness of multiple myeloma therapies through cytochrome P450 induction 1, 2.
Avoid These Enzyme-Inducing AEDs:
- Phenytoin - reduces levels of taxanes, Vinca alkaloids, methotrexate, teniposide, and camptothecin; additionally, cisplatin and corticosteroids (commonly used in myeloma) can reduce phenytoin effectiveness, creating bidirectional problems 1, 2
- Carbamazepine - similar enzyme induction profile
- Phenobarbital - potent enzyme inducer affecting multiple chemotherapy agents
Preferred Non-Enzyme-Inducing AEDs:
- Levetiracetam - first-line choice; no P450 metabolism, no significant drug interactions 1, 2
- Gabapentin - renally excreted, minimal interactions (dose adjust for renal impairment common in myeloma)
- Lamotrigine - minimal enzyme effects
- Pregabalin - similar profile to gabapentin
- Topiramate - generally safe option
- Zonisamide - acceptable alternative
Critical Drug Interactions to Recognize
Valproate Considerations:
While valproate is non-enzyme-inducing and was historically considered first-choice 2, it can increase toxicity of etoposide and nitrosoureas through enzyme inhibition 1, 2. Given that myeloma patients may receive various chemotherapy regimens, levetiracetam or gabapentin are safer first-line choices.
Bidirectional Interactions:
- 5-fluorouracil increases phenytoin toxicity 1, 2
- Methotrexate reduces valproate effectiveness 1, 2
- Corticosteroids (dexamethasone is backbone of myeloma therapy in VRd, DRd regimens 3, 4) reduce phenytoin levels 1, 2
Dosing Approach
Standard dosing applies for non-enzyme-inducing AEDs, with these myeloma-specific considerations:
- Renal function: Multiple myeloma frequently causes renal impairment 4. For renally-cleared AEDs (gabapentin, pregabalin, levetiracetam), adjust doses according to creatinine clearance
- Levetiracetam: Start 500 mg twice daily, titrate to 1000-1500 mg twice daily based on seizure control and renal function
- Gabapentin: Start 300 mg three times daily, titrate up to 900-1800 mg three times daily; requires aggressive dose reduction in renal impairment
Common Pitfalls to Avoid
Don't assume older AEDs are acceptable - The evidence clearly shows enzyme-inducing AEDs compromise chemotherapy efficacy, potentially affecting survival 1, 2
Don't overlook polypharmacy risks - Myeloma patients are elderly with multiple comorbidities and inevitable polypharmacy 5. CNS-affecting drugs increase fall risk, which is critical given the high incidence of bone disease in myeloma 4
Don't forget to reassess renal function - Myeloma therapy can improve or worsen renal function 4, requiring AED dose adjustments throughout treatment
If enzyme-inducing AEDs must be used (rare circumstances), anticipate needing higher doses of chemotherapy agents 1, though this approach is not recommended given safer alternatives exist
Algorithm Summary
- Patient with multiple myeloma develops seizures → Check renal function
- First-line: Levetiracetam (standard dosing, adjust for CrCl <80)
- Alternative: Gabapentin (if neuropathic pain also present) or lamotrigine
- Avoid entirely: Phenytoin, carbamazepine, phenobarbital
- Use valproate cautiously: Only if other options fail and patient not receiving etoposide/nitrosoureas
- Monitor: Seizure control, drug levels if applicable, renal function, and chemotherapy response